Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951841 | 0.85 | MAPK1 (0.63) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL2338659 | 0.79 | MAPK1 (0.65) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL269695 | 0.79 | MAPK1 (0.65) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL10512497 | 0.75 | MAPK1 (0.64) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL12012125 | 0.74 | MAPK1 (0.62) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL952278 | 0.73 | MAPK1 (1.00) | MAPK1ALOX15CYP1A2HCRTR1 | |
| Bromide SCHEMBL2334813 | 0.73 | MAPK1 (0.61) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL21894538 | 0.73 | ALOX12 (0.59) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL17554526 | 0.69 | ALOX12 (0.59) | MAPK1ALOX12ALOX15CYP1A2TDP1 | |
| SCHEMBL21760698 | 0.69 | ALOX12 (0.59) | MAPK1ALOX12ALOX15CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | MAPK1 38/4885ALOX12 4268/4885ALOX15 4056/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | MAPK1 102/4885ALOX12 298/4885ALOX15 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.